Analysts have been eager to weigh in on the Healthcare sector with new ratings on Clover Health Investments (CLOV – Research Report) and Biomea Fusion (BMEA – Research Report).
Clover Health Investments (CLOV)
In a report issued on December 1, Jason Cassorla from Citi maintained a Hold rating on Clover Health Investments, with a price target of $1.00. The company’s shares closed last Friday at $0.95.
According to TipRanks.com, Cassorla has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Clover Health Investments is a Moderate Buy with an average price target of $1.33.
See the top stocks recommended by analysts >>
Biomea Fusion (BMEA)
In a report issued on December 1, Yigal Nochomovitz from Citi reiterated a Buy rating on Biomea Fusion, with a price target of $90.00. The company’s shares closed last Friday at $16.68.
According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of
Biomea Fusion has an analyst consensus of Strong Buy, with a price target consensus of $54.33, representing a 250.3% upside. In a report issued on November 22, Oppenheimer also maintained a Buy rating on the stock with a $70.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLOV:
- Clover Health to exit CMS ACO REACH Program at end of 2023
- Clover Health price target lowered to $1 from $1.50 at Citi
- Clover Health price target lowered to $2 from $3 at Canaccord
- Clover Health reports Q3 revenue $482.07M, consensus $494.6M
- Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance
